BI-1206
Non-Hodgkin's Lymphoma
Key Facts
About BioInvent International
BioInvent International is a clinical-stage biotechnology company with a mission to transform cancer treatment through the discovery and development of novel, targeted antibody therapies. The company's strategy is anchored in its proprietary F.I.R.S.T.™ and n-CoDeR® platforms, which enable the identification of biologically relevant targets and the generation of fully human antibodies directly from human tissue. BioInvent has advanced a pipeline of proprietary and partnered candidates, most notably the anti-FcγRIIB antibody BI-1206, positioning itself as a key player in the next wave of immuno-oncology innovation.
View full company profileAbout BioInvent International
BioInvent International is a clinical-stage biotechnology company with a mission to transform cancer treatment through the discovery and development of novel, targeted antibody therapies. The company's strategy is anchored in its proprietary F.I.R.S.T.™ and n-CoDeR® platforms, which enable the identification of biologically relevant targets and the generation of fully human antibodies directly from human tissue. BioInvent has advanced a pipeline of proprietary and partnered candidates, most notably the anti-FcγRIIB antibody BI-1206, positioning itself as a key player in the next wave of immuno-oncology innovation.
View full company profileTherapeutic Areas
Other Non-Hodgkin's Lymphoma Drugs
| Drug | Company | Phase |
|---|---|---|
| ACE1831 | Acepodia | Phase I |
| SP-3164 | Sumitomo Pharma | Phase 1/2 |